Loading patent…
AssigneeHollis-Eden Pharmaceuticals, Inc.
InventorsJaime Flores-Riveros, James M. Frincke, Christopher L. Reading, Dwight Stickney
Estimating the term…
The invention provides, inter alia, methods to treat, e.g., hyperglycemia or diabetes patients having two or more of a BMI of at least 28 or 29, a fasting insulin level of at least 4 μU/mL or at least 6 μU/mL and optionally (i) a serum MCP1 level of at least about 400 pg/mL or at least about 500 pg/mL. The treatment method includes administering 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol and optionally another compound such as metformin or glyburide. Specific embodiments include use of 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol for the treatment of hypercholesterolemia in a patient and a BMI of at least 28 or 29 and optionally hyperglycemia. In these embodiments, the patient will most preferably have a fasting insulin level of at least 4 μU/mL or at least 5 μU/mL.
A method to treat a patient(s) having diabetes, hyperglycemia, a macrovascular disease, a microvascular disease, nonalcoholic steatohepatitis, acute alcoholic hepatitis or a dyslipidemia condition, comprising,
Use of a compound for the preparation of a medicament for the treatment of diabetes, hyperglycemia, macrovascular disease, microvascular disease, nonalcoholic steatohepatitis or acute alcoholic hepatitis or a hyperlipidemia condition in patient(s) having (i) a BMI of at least about 28, and (ii) a fasting blood insulin level of at least about 4 μU/mL and/or a fasting blood C peptide level of at least about 2 ng/mL, wherein the compound is 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol, 17α-ethynylandrost-5-ene-3β, 7β, 16α, 17β-tetrol, 17α-ethynylandrost-5-ene-3α,7β,16α, 17β-tetrol, androst-5-ene-3β, 7β, 16α, 17β-tetrol or androst-5-ene-3α,7β,16α, 17β-tetrol.
A method to treat hyperglycemia, diabetes, dyslipidemia, a macrovascular disease, a microvascular disease, nonalcoholic steatohepatitis or acute alcoholic hepatitis in a patient(s) in need thereof comprising administering an amount of 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol sufficient to maintain a serum level of about 0.5 ng/mL to about 200 ng/mL for about 2 hours to at least about 4 hours.
A pharmaceutical formulation for oral administration comprising one or more excipients and 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol in an amount sufficient to maintain a serum level in a patient of about 0.5 ng/mL to about 200 ng/mL for about 2 hours to at least about 4 hours.
Dependencies are inferred from the claim text.